Since IL-6 regulates circulating hepcidin levels under tumor conditions, blocking IL-6 with monoclonal antibodies tocilizumab or siltuximab may be suitable for the management of cancer-associated anemia. This evidence concerns the gene HAMP and anemia (phenotype).